Roche's Atezolizumab Makes Its Mark On The PD1/L1 Field
This article was originally published in Scrip
Executive Summary
Roche/ Genentech's anti-PD-L1 product atezolizumab that Roche's is shaping up as a meaningful competitor to the frontrunners Opdivo and Keytruda in lung cancer and could move ahead in bladder cancer, data presented at the ECC meeting in Vienna this weekend suggest.